modelTeriparatide
Extends from Pharmacolibrary.Drugs.ATC.H.H05AA02.
Information
| name: | Teriparatide | |
| ATC code: | H05AA02 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 0.02 | mg |
| volume of distribution: | 9.4 | L |
| clearance: | 62 | L/hr |
| other parameters in model implementation | ||
Teriparatide is a recombinant form of parathyroid hormone (PTH 1-34) used primarily for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture. It stimulates new bone formation by acting on osteoblasts. Teriparatide is approved and widely used in clinical practice today.
Pharmacokinetics
Pharmacokinetic parameters following a single subcutaneous dose of 20 mcg in healthy adult volunteers (both sexes).
References
Fenwick, S, et al., & Nath, A (2023). Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 34(1) 179–188. DOI:10.1007/s00198-022-06573-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/36287230
Kumagai, Y, et al., & Sugimoto, T (2020). Safety Profiles, Pharmacokinetics, and Changes in Bone Turnover Markers After Twice-Weekly Subcutaneous Administration of Teriparatide in Healthy Japanese Postmenopausal Women: A Single-Blind Randomized Study. Clinical pharmacology in drug development 9(1) 87–96. DOI:10.1002/cpdd.687 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30921502
Ose, A, et al., & Tanigawara, Y (2017). Population Pharmacokinetic and Exposure-Response Analysis of Weekly Teriparatide in Osteoporosis Patients. Journal of clinical pharmacology 57(12) 1545–1553. DOI:10.1002/jcph.949 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28614613
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)